"
Team:SupBiotech-Paris/Acknowledgement
From 2009.igem.org
(Difference between revisions)
| Line 2: | Line 2: | ||
{{Template:Supbiotechparis}} | {{Template:Supbiotechparis}} | ||
| - | + | {| | |
| - | We want to acknowledge : | + | |We want to acknowledge : |
| - | '''UMR8121 from the Gustave Roussy Institute''' | + | |- |
| - | Thanks a lot to: | + | | |
| + | |} | ||
| + | {| | ||
| + | |'''UMR8121 from the Gustave Roussy Institute''' | ||
| + | |- | ||
| + | |Thanks a lot to: | ||
| + | |} | ||
*Lluis Mir | *Lluis Mir | ||
*Karim | *Karim | ||
Revision as of 14:18, 19 August 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
| We want to acknowledge : |
| UMR8121 from the Gustave Roussy Institute |
| Thanks a lot to: |
- Lluis Mir
- Karim
Our Sponsors
- Embassy of France in Washington [http://fr.ambafrance-us.org/spip.php?rubrique=[Link]]
- Eurogentec [http://www.eurogentec.com/eu-home.html [Link]]
- Takara [http://www.takarabioeurope.com/ [Link]]
- Clonetec[http://www.clontech.com/ [Link]]
- Promega [http://www.promega.com/ [Link]]
- Sigma-Aldrich [http://www.sigmaaldrich.com/ [Link]]
- Qiagen [http://www1.qiagen.com/ [Link]]
